Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Artichoke leaf extract (ALE) is a botanical preparation derived from the leaves of *Cynara scolymus* (or *Cynara cardunculus*), containing bioactive polyphenols such as cynarin, chlorogenic acid, and flavonoids like luteolin. It is primarily utilized as a nutraceutical for its hepatoprotective, lipid-lowering, and antioxidant properties. The extract exerts its effects by inhibiting HMG-CoA reductase to lower cholesterol, stimulating bile production (choleretic effect), and activating the Nrf2/HO-1 antioxidant signaling pathway. ALE has been clinically investigated for the management of non-alcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated steatotic liver disease (MASLD), and hypercholesterolemia. While widely available as a dietary supplement, its clinical efficacy in reducing LDL cholesterol has shown mixed results in various populations, leading to ongoing research into standardized formulations like Pycrinil and Altilix.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on artichoke leaf extract.